$531.8 M

UROV Mkt cap, 01-Apr-2021
Urovant Sciences Net income (FY, 2020)-146.7 M
Urovant Sciences Cash, 31-Mar-202051.4 M
Urovant Sciences EV483.8 M
Get notified regarding key financial metrics and revenue changes at Urovant SciencesLearn more
Banner background

Urovant Sciences Income Statement

Annual

USDFY, 2017FY, 2018FY, 2019FY, 2020

R&D expense

26.0m32.4m92.2m92.4m

General and administrative expense

1.0m4.6m18.6m46.3m

Operating expense total

27.1m37.0m110.8m138.7m

Interest expense

259.0k3.6m

Pre tax profit

(27.0m)(37.0m)(111.3m)(146.7m)

Income tax expense

37.2k47.0k65.0k

Net Income

(27.0m)(37.1m)(111.3m)(146.7m)

Quarterly

USDQ1, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

R&D expense

3.1m28.0m20.7m21.3m22.0m17.8m23.1m

General and administrative expense

334.1k3.5m3.7m4.9m5.5m7.4m16.7m

Operating expense total

3.5m31.5m24.3m26.2m27.5m25.2m39.8m

Interest expense

309.0k513.0k581.0k1.4m

Pre tax profit

(3.6m)(31.2m)(24.6m)(26.4m)(28.4m)(25.7m)(41.2m)

Income tax expense

2.1k55.4k5.0k61.0k67.0k8.0k38.0k

Net Income

(3.6m)(31.3m)(24.6m)(26.4m)(28.5m)(25.7m)(41.3m)

Urovant Sciences Balance Sheet

Annual

USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

4.8m7.2m85.4m51.4m

Prepaid Expenses

8.6k5.2m12.9m6.5m

Current Assets

4.8m12.4m98.5m58.3m

PP&E

509.6k923.0k1.2m

Total Assets

4.8m13.0m100.1m63.3m

Accounts Payable

15.9k832.8k1.9m1.6m

Short-term debt

351.0k

Current Liabilities

11.8m30.9m

Long-term debt

13.5m3.1m

Total Debt

13.5m3.4m

Total Liabilities

866.4k5.9m25.4m121.3m

Common Stock

100.0750.01.0k1.0k

Additional Paid-in Capital

31.0m72.6m250.0m263.8m

Retained Earnings

(27.1m)(64.2m)(175.5m)(322.3m)

Total Equity

3.9m7.1m74.8m(58.0m)

Debt to Equity Ratio

0.2 x

Debt to Assets Ratio

0.1 x

Financial Leverage

1.2 x1.8 x1.3 x-1.1 x

Quarterly

USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

4.3m1.7m95.6m62.4m67.8m131.9m

Prepaid Expenses

5.9m11.8m15.1m8.4m8.8m10.2m

Current Assets

11.0m15.6m111.0m71.0m76.9m142.5m

PP&E

585.2k587.0k571.0k1.2m1.2m1.2m

Total Assets

11.7m16.3m112.3m76.3m82.0m147.6m

Accounts Payable

5.3m5.1m3.7m3.0m1.6m2.4m

Short-term debt

10.0k43.8m

Current Liabilities

11.4m11.6m61.5m

Long-term debt

17.1m46.7m90.5m

Total Debt

17.1m43.4m134.2m

Total Liabilities

16.8m23.0m10.1m28.5m58.3m152.0m

Common Stock

750.01.0k1.0k1.0k1.0k1.0k

Additional Paid-in Capital

91.9m114.6m248.4m251.3m253.1m266.2m

Retained Earnings

(95.5m)(120.1m)(146.6m)(204.0m)(229.8m)(271.0m)

Total Equity

5.1m(6.7m)102.2m47.7m23.8m(4.4m)

Debt to Equity Ratio

0.4 x1.8 x

Debt to Assets Ratio

0.2 x0.5 x

Financial Leverage

2.3 x-2.4 x1.1 x1.6 x3.5 x-33.2 x

Urovant Sciences Cash Flow

Annual

USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(27.0m)(37.1m)(111.3m)(146.7m)

Depreciation and Amortization

12.4k180.0k246.0k

Accounts Payable

15.9k816.9k1.1m(336.0k)

Cash From Operating Activities

(25.3m)(34.1m)(109.0m)(102.1m)

Purchases of PP&E

(522.0k)

Cash From Investing Activities

(593.0k)(769.0k)

Long-term Borrowings

(47.9m)

Cash From Financing Activities

30.0m37.0m188.6m68.9m

Net Change in Cash

4.8m2.4m79.0m(33.9m)

Interest Paid

169.0k3.1m

Income Taxes Paid

20.0k178.0k65.0k

Quarterly

USDQ1, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(3.6m)(31.3m)(55.9m)(82.4m)(28.5m)(54.2m)(95.5m)

Depreciation and Amortization

85.0k132.0k54.0k113.0k178.0k

Accounts Payable

114.2k4.2m3.8m2.9m834.0k(358.0k)463.0k

Cash From Operating Activities

(600.6k)(20.8m)(44.3m)(85.1m)(22.5m)(47.0m)(70.5m)

Purchases of PP&E

(115.4k)(162.0k)

Cash From Investing Activities

(162.0k)(193.0k)(278.0k)(589.0k)(732.0k)

Cash From Financing Activities

34.9k17.9m39.0m174.5m(187.0k)30.0m117.9m

Net Change in Cash

(565.7k)(2.9m)(5.5m)89.3m(23.0m)(17.5m)46.6m

Interest Paid

385.0k867.0k1.6m

Income Taxes Paid

155.0k174.0k50.0k61.0k

Urovant Sciences Ratios

USDFY, 2017

Financial Leverage

1.2 x

Urovant Sciences Operating Metrics

Q1, 2019

Phase III Patients Enrolled

1.4 k